Keryx Biopharma - KERX

[coxy]

+0.57 (16.42%)

perche' sei cosi' pessimista?

 

[Vuze]

perche' sei cosi' pessimista?

era un dato provvisorio

 

[coxy]

era un dato provvisorio

imho molto provvisorio...
segui un po' te la bestia..almeno per i prossimi 28 giorni...notizie di eventuali risultati...gossip...'uttanate dei guru etc etc.
mo' nicox o morte(agli altri, of course).
scusa il tono un po' emozionale ma ho i lapis a quadriglie'...

 

[Vuze]

Keryx Biopharmaceuticals Inc. and AEterna Zentaris Inc. said Monday regulators have given a "fast track" designation to the drug candidate perifosine as a potential treatment for refractory advanced colorectal cancer.
The designation allows the Food and Drug Administration to conduct a faster review of a potential treatment intended for a serious or life-threatening disease. Drug developers can submit their applications to the FDA piece by piece instead of having to file all the paperwork at once.
Keryx, which is based in New York, and AEterna Zentaris, a Canadian company, are partnering on perifosine in North America. AEterna Zentaris has the rights to the drug in the rest of the world excluding South Korea.
A late-stage trial of the drug will start this quarter and be completed in the second half of 2011, Keryx said in a statement.
In December, perifosine received a fast-track review designation as a potential treatment for multiple myeloma.
Perifosine also has orphan drug status, which is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market. Incentives include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits.
Keryx shares climbed 67 cents, or 24 percent, to $3.41 in Monday morning trading. AEterna Zentaris stock rose 20 cents, or almost 25 percent, to $

 

[Vuze]

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of Zerenex (ferric citrate) at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings

http://www.prnewswire.com/news-releases/keryx-biopharmaceuticals-announces-poster-presentations-highlighting-clinical-activity-of-zerenex-ferric-citrate-at-national-kidney-foundation-nkf-2010-spring-clinical-meetings-90733959.html

 

[coxy]

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of Zerenex (ferric citrate) at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings

http://www.prnewswire.com/news-releases/keryx-biopharmaceuticals-announces-poster-presentations-highlighting-clinical-activity-of-zerenex-ferric-citrate-at-national-kidney-foundation-nkf-2010-spring-clinical-meetings-90733959.html

very very good. aspettiamo di leggere i dati. se son buoni....due farmaci nel 2012....speriamo di arrivarci, non vorrei un buy out troppo precoce

 

[Aeiou]

very very good. aspettiamo di leggere i dati. se son buoni....due farmaci nel 2012....speriamo di arrivarci, non vorrei un buy out troppo precoce

Æterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Program with Perifosine in Multiple Myeloma

 

[paologorgo]

volevo segnalare, a chi eventualmente fosse interessato, che l'azienda si sta promuovendo, attraverso articoli redazionali, sui più prestigiosi ed importanti blog di finanza in lingua Inglese:

Nortia Research: Sponsored Post: Keryx Biopharma (NASDAQ:KERX) Product Development Update

vabbè, ho esagerato un po'...

 

[Vuze]

non rimaniamo fermi su nicox
questo è un bel titolo

 

[guly]

non rimaniamo fermi su nicox
questo è un bel titolo

hai perfettamente ragione.qui c'e'meno rischio e meno ma molte meno incognite.pipeline piu' ricca.azienda piu' dinamica.non c'e' che dire.